Eurofins Scientific Se · EURONEXT:ERF
Eurofins Scientific — Q1 2021 Earnings Presentation
12 slides from Eurofins Scientific's earnings presentation, Apr 28, 2021
Slide 1: Q1 2021 Management Update
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2021. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its af
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on
Slide 3: Key operational highlights
Key operational highlights • Eurofins remained very active in fighting the pandemic throughout Q1 2021: ➢ Set up very high throughput SARS-CoV-2 NGS1 capacity and won large contracts to support several countries and institutions to monitor and identify the emergence and spread of new Variants of Int
Slide 4: Key financial highlights
Key financial highlights Key Highlights • Strong revenues in Q1 of EUR 1,614m, +41.3% year-on-year, despite a foreign exchange headwind of -3.7% (Q1 2021 vs. Q1 2020 average FX rates) • Very strong organic revenue growth1 of 44.3% in Q1 2021 reflecting the significant Revenue, EUR m contribution fro
Slide 5: COVID-19 related business developments: innovation and product launches
COVID-19 related business developments: innovation and product launches • GSD NovaPrime®, successfully validated for pharynx gargle and saliva samples • GSD NovaLisa®, a quantitative antibody ELISA kit to measure immune response to COVID-19 and vaccines ➢ CE marked serological assay ➢ Supports vacci
Slide 6: COVID-19 related business developments: SAFER@WORK™
COVID-19 related business developments: SAFER@WORK™ • Through its SAFER@WORK™ programmes, Eurofins continues to enable many industries to sustain or re-start operations • Over 3,200 SAFER@WORK™ contracts with potential revenues of up to EUR 550m, signed or in final stage, across 36 countries • Signi
Slide 7: Our ongoing ESG commitment
Our ongoing ESG commitment 1. Embed ESG targets into leadership performance and remuneration from 2021 2. Commitment to achieve Carbon neutrality by 2025: a. Launch a carbon footprint reduction programme at regional level, managed by our Business Leaders b. Establish a CO2 inventory (scope 1, 2, 3)
Slide 8: Outlook: objectives remain unchanged at this time
Outlook: objectives remain unchanged at this time Increasingly likely that 2021 objectives will be materially exceeded and significant levels of testing for COVID-19 may continue well beyond Q1 2021. The exact impact and timing of vaccination, new variants of concern and public health policy decisio
Slide 9: Conclusions
Conclusions • Continued strong financial performance in Q1 2021, with Core Business1 delivering organic growth close to 10% in Q1 2021 and 44.3% overall • Strong operational performance in Q1 2021 ➢ Rapidly accelerating growth of the Group’s Core Business ➢ Continued significant contribution from CO
Slide 10: Q&A
Q&A CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 10
Slide 11: Appendix
Appendix CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd 2021. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 11
Slide 12: Definitions / Alternative Performance Measures (APMs)
Definitions / Alternative Performance Measures (APMs) Eurofins is providing in the consolidated financial statements certain alternative performance measures (non-IFRS information). APMs used in the Consolidated Income Statement Adjusted results – reflect the ongoing performance of the mature and re